Search Results - "Mark Gilbert"

IDH mutation in glioma: molecular mechanisms and potential therapeutic targets by Han, Sue, Liu, Yang, Cai, Sabrina J., Qian, Mingyu, Ding, Jianyi, Larion, Mioara, Gilbert, Mark R., Yang, Chunzhang

“…Isocitrate dehydrogenase (IDH) enzymes catalyse the oxidative decarboxylation of isocitrate and therefore play key roles in the Krebs cycle and cellular…”
Get full text

Biology and management of ependymomas by Wu, Jing, Armstrong, Terri S, Gilbert, Mark R

“…Ependymomas are rare primary tumors of the central nervous system in children and adults that comprise histologically similar but genetically distinct…”
Get full text

Modeling YAP fusions: a paradigm for investigating rare cancers? by Sahebjam, Solmaz, Gilbert, Mark R

“…Loss of the tumor suppressor gene is a common finding in meningiomas, and more recently fusions have been found in a subset of pediatric wild-type meningiomas…”
Get full text

Bayesian Optimal Interval Design: A Simple and Well-Performing Design for Phase I Oncology Trials by Yuan, Ying, Hess, Kenneth R, Hilsenbeck, Susan G, Gilbert, Mark R

“…Despite more than two decades of publications that offer more innovative model-based designs, the classical 3 + 3 design remains the most dominant phase I…”
Get full text

cIMPACT‐NOW update 7: advancing the molecular classification of ependymal tumors by Ellison, David W., Aldape, Kenneth D., Capper, David, Fouladi, Maryam, Gilbert, Mark R., Gilbertson, Richard J., Hawkins, Cynthia, Merchant, Thomas E., Pajtler, Kristian, Venneti, Sriram, Louis, David N.

“…Advances in our understanding of the biological basis and molecular characteristics of ependymal tumors since the latest iteration of the World Health…”
Get full text

Randomized Double-Blind Placebo-Controlled Trial of Bevacizumab Therapy for Radiation Necrosis of the Central Nervous System by Levin, Victor A., M.D, Bidaut, Luc, Ph.D, Hou, Ping, Ph.D, Kumar, Ashok J., M.D, Wefel, Jeffrey S., Ph.D, Bekele, B. Nebiyou, Ph.D, Prabhu, Sujit, M.D, Loghin, Monica, M.D, Gilbert, Mark R., M.D, Jackson, Edward F., Ph.D

“…Purpose To conduct a controlled trial of bevacizumab for the treatment of symptomatic radiation necrosis of the brain. Methods and Materials A total of 14…”
Get full text

Disparities in the availability and access to Neuro-Oncology Trial-Supporting infrastructure in the United States by Kim, Yeonju, Armstrong, Terri S, Gilbert, Mark R, Celiku, Orieta

“…We conducted an extensive assessment and quantification of the reach of the oncology clinical trial supporting infrastructure in the United States (US). While…”
Get full text

Immunotherapy in CNS cancers: the role of immune cell trafficking by Ratnam, Nivedita M, Gilbert, Mark R, Giles, Amber J

“…Abstract Glioblastoma (GBM) is a highly malignant CNS tumor with very poor survival despite intervention with conventional therapeutic strategies. Although the…”
Get full text

Hippocampal Avoidance During Whole-Brain Radiotherapy Plus Memantine for Patients With Brain Metastases: Phase III Trial NRG Oncology CC001 by Brown, Paul D, Gondi, Vinai, Pugh, Stephanie, Tome, Wolfgang A, Wefel, Jeffrey S, Armstrong, Terri S, Bovi, Joseph A, Robinson, Cliff, Konski, Andre, Khuntia, Deepak, Grosshans, David, Benzinger, Tammie L S, Bruner, Deborah, Gilbert, Mark R, Roberge, David, Kundapur, Vijayananda, Devisetty, Kiran, Shah, Sunjay, Usuki, Kenneth, Anderson, Bethany Marie, Stea, Baldassarre, Yoon, Harold, Li, Jing, Laack, Nadia N, Kruser, Tim J, Chmura, Steven J, Shi, Wenyin, Deshmukh, Snehal, Mehta, Minesh P, Kachnic, Lisa A

“…Radiation dose to the neuroregenerative zone of the hippocampus has been found to be associated with cognitive toxicity. Hippocampal avoidance (HA) using…”
Get full text

Antiangiogenic Therapy for Glioblastoma: Complex Biology and Complicated Results by Gilbert, Mark R

Get full text

Hypoxia in the glioblastoma microenvironment: shaping the phenotype of cancer stem-like cells by Colwell, Nicole, Larion, Mioara, Giles, Amber J, Seldomridge, Ashlee N, Sizdahkhani, Saman, Gilbert, Mark R, Park, Deric M

“…Glioblastoma is the most common and aggressive malignant primary brain tumor. Cellular heterogeneity is a characteristic feature of the disease and contributes…”
Get full text

Computational modeling demonstrates that glioblastoma cells can survive spatial environmental challenges through exploratory adaptation by Celiku, Orieta, Gilbert, Mark R., Lavi, Orit

“…Glioblastoma (GBM) is an aggressive type of brain cancer with remarkable cell migration and adaptation capabilities. Exploratory adaptation—utilization of…”
Get full text

A critical analysis of neuro-oncology clinical trials by Kim, Yeonju, Armstrong, Terri S, Gilbert, Mark R, Celiku, Orieta

“…Abstract Background Limitations in trial design, accrual, and data reporting impact efficient and reliable drug evaluation in cancer clinical trials. These…”
Get full text

Dose-Dense Temozolomide for Newly Diagnosed Glioblastoma: A Randomized Phase III Clinical Trial by GILBERT, Mark R, MEIHUA WANG, MAHAJAN, Anita, SCHULTZ, Christopher J, ERRIDGE, Sara, BAUMERT, Brigitta, HOPKINS, Kristen I, TZUK-SHINA, Tzahala, BROWN, Paul D, CHAKRAVARTI, Arnab, CURRAN, Walter J, MEHTA, Minesh P, ALDAPE, Kenneth D, STUPP, Roger, HEGI, Monika E, JAECKLE, Kurt A, ARMSTRONG, Terri S, WEFEL, Jeffrey S, MINHEE WON, BLUMENTHAL, Deborah T

“…Radiotherapy with concomitant and adjuvant temozolomide is the standard of care for newly diagnosed glioblastoma (GBM). O(6)-methylguanine-DNA…”
Get full text

A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma by Gilbert, Mark R, Dignam, James J, Armstrong, Terri S, Wefel, Jeffrey S, Blumenthal, Deborah T, Vogelbaum, Michael A, Colman, Howard, Chakravarti, Arnab, Pugh, Stephanie, Won, Minhee, Jeraj, Robert, Brown, Paul D, Jaeckle, Kurt A, Schiff, David, Stieber, Volker W, Brachman, David G, Werner-Wasik, Maria, Tremont-Lukats, Ivo W, Sulman, Erik P, Aldape, Kenneth D, Curran, Walter J, Mehta, Minesh P

“…The addition of bevacizumab to temozolomide and radiotherapy did not improve overall survival in patients with glioblastoma. Patients receiving bevacizumab had…”
Get full text

Chemoradiotherapy in Malignant Glioma: Standard of Care and Future Directions by Stupp, Roger, Hegi, Monika E, Gilbert, Mark R, Chakravarti, Arnab

“…Glioma has been considered resistant to chemotherapy and radiation. Recently, concomitant and adjuvant chemoradiotherapy with temozolomide has become the…”
Get full text

T cell exhaustion in malignant gliomas by Watowich, Matthew B, Gilbert, Mark R, Larion, Mioara

“…Despite advances in understanding tumor biology, malignant gliomas remain incurable. While immunotherapy has improved outcomes in other cancer types,…”
Get more information

Management of Idiopathic Vocal Process Granuloma: A Survey of Academic Laryngologists by Boyce, Claire, Schmidt, Kelly L., Gilbert, Mark R.

“…Objectives Vocal process granulomas (VPGs) are benign laryngeal lesions that may manifest as ulcerated regions of the vocal fold or nodular polypoid lesions…”
Get full text

Radiation plus Procarbazine, CCNU, and Vincristine in Low-Grade Glioma by Buckner, Jan C, Shaw, Edward G, Pugh, Stephanie L, Chakravarti, Arnab, Gilbert, Mark R, Barger, Geoffrey R, Coons, Stephen, Ricci, Peter, Bullard, Dennis, Brown, Paul D, Stelzer, Keith, Brachman, David, Suh, John H, Schultz, Christopher J, Bahary, Jean-Paul, Fisher, Barbara J, Kim, Harold, Murtha, Albert D, Bell, Erica H, Won, Minhee, Mehta, Minesh P, Curran, Walter J

“…Patients with grade 2 glioma were randomly assigned to radiation therapy alone or radiation therapy plus six cycles of chemotherapy. The median overall…”
Get full text

Comprehensive Genomic Analysis in NRG Oncology/RTOG 9802: A Phase III Trial of Radiation Versus Radiation Plus Procarbazine, Lomustine (CCNU), and Vincristine in High-Risk Low-Grade Glioma by Bell, Erica H, Zhang, Peixin, Shaw, Edward G, Buckner, Jan C, Barger, Geoffrey R, Bullard, Dennis E, Mehta, Minesh P, Gilbert, Mark R, Brown, Paul D, Stelzer, Keith J, McElroy, Joseph P, Fleming, Jessica L, Timmers, Cynthia D, Becker, Aline P, Salavaggione, Andrea L, Liu, Ziyan, Aldape, Kenneth, Brachman, David G, Gertler, Stanley Z, Murtha, Albert D, Schultz, Christopher J, Johnson, David, Laack, Nadia N, Hunter, Grant K, Crocker, Ian R, Won, Minhee, Chakravarti, Arnab

“…NRG Oncology/RTOG 9802 (ClinicalTrials.gov Identifier: NCT00003375) is a practice-changing study for patients with WHO low-grade glioma (LGG, grade II), as it…”
Get full text